Edwards Lifesciences Quarterly Income Statement
NYSE: EWHealth CareIndustrial SpecialtiesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Edwards Lifesciences revenue and earnings
In the quarter ended Jun 30, 2026, Edwards Lifesciences generated $1.74 billion in revenue, up 13.6% from the same quarter a year earlier. Net income was $241.9 million (-27.4% year over year), for a net margin of 13.9% versus a median of 21.7% in the prior 5 quarters. Gross margin was 77.5% (down from 77.5%) and operating margin 29.5%.
Diluted earnings per share came in at $0.42, down from $0.56.
Summary generated from market data by MetaCap's automated system. Methodology
Edwards Lifesciences income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.74B | 1.65B | 1.57B | 1.55B | 1.53B | 1.41B | 1.39B | 1.35B | 1.37B | 1.33B | 1.27B | 1.24B |
| Revenue growth (YoY) | +13.63% | +16.70% | +13.26% | +14.67% | +11.89% | +6.23% | +9.43% | +8.93% | +7.08% | +8.89% | +194.58% | -5.73% |
| Cost of Revenue | 392.40M | 362.60M | 343.00M | 345.20M | 344.40M | 301.60M | 292.20M | 262.90M | 275.50M | 286.90M | 251.00M | 250.60M |
| Gross Profit | 1.35B | 1.29B | 1.23B | 1.21B | 1.19B | 1.11B | 1.09B | 1.09B | 1.09B | 1.04B | 1.02B | 992.80M |
| Operating Expenses | 835.40M | 808.40M | 1.08B | 900.80M | 776.60M | 716.30M | 781.00M | 740.90M | 727.40M | 694.00M | 668.60M | 626.90M |
| Research & Development | 278.90M | 263.30M | 267.70M | 280.70M | 276.20M | 254.60M | 271.10M | 253.40M | 271.80M | 256.70M | 242.10M | 242.80M |
| Selling, General & Admin | 561.20M | 522.20M | 602.90M | 514.60M | 502.00M | 465.70M | 491.90M | 421.40M | 447.50M | 428.40M | 416.60M | 381.90M |
| Operating Income | 513.20M | 477.60M | 151.10M | 307.10M | 411.20M | 394.80M | 312.60M | 350.60M | 366.50M | 349.00M | 346.80M | 365.90M |
| Other Income (Expense) | 6.60M | -18.60M | -60.70M | 41.30M | -11.00M | 39.10M | 77.50M | 52.20M | 17.50M | 22.20M | 3.60M | 6.60M |
| Pretax Income | 519.80M | 459.00M | 90.40M | 348.40M | 400.20M | 433.90M | 390.10M | 402.80M | 384.00M | 371.20M | 367.20M | 387.60M |
| Income Tax | 278.40M | 78.30M | 26.20M | 56.10M | 64.30M | 70.30M | 45.10M | 40.70M | 20.00M | 46.30M | 34.10M | 52.70M |
| Net Income | 241.90M | 380.70M | 91.20M | 291.10M | 333.20M | 358.00M | 385.60M | 3.07B | 366.30M | 351.90M | 369.90M | 384.90M |
| Net Income growth (YoY) | -27.40% | +6.34% | -76.35% | -90.52% | -9.04% | +1.73% | +4.24% | +697.82% | +19.28% | +3.35% | -7.15% | +12.05% |
| EPS (Basic) | 0.42 | 0.66 | 0.16 | 0.50 | 0.57 | 0.61 | 0.65 | 5.14 | 0.61 | 0.58 | 0.61 | 0.63 |
| EPS (Diluted) | 0.42 | 0.66 | 0.16 | 0.50 | 0.56 | 0.61 | 0.65 | 5.13 | 0.61 | 0.58 | 0.61 | 0.63 |
| Shares Outstanding (Basic) | 576.40M | 579.20M | — | 584.70M | 587.00M | 586.90M | — | 597.20M | 602.10M | 601.60M | — | 607.00M |
| Shares Outstanding (Diluted) | 577.60M | 580.70M | — | 585.70M | 587.90M | 587.80M | — | 598.10M | 604.30M | 604.10M | — | 609.50M |
| EBITDA | 555.90M | 518.50M | 193.80M | 346.30M | 449.30M | 431.40M | 355.20M | 385.10M | 406.10M | 387.50M | 383.50M | 402.80M |
| Gross Margin | 77.46% | 78.01% | 78.15% | 77.77% | 77.52% | 78.65% | 78.91% | 80.59% | 79.88% | 78.43% | 80.18% | 79.85% |
| Operating Margin | 29.48% | 28.97% | 9.63% | 19.77% | 26.84% | 27.95% | 22.56% | 25.89% | 26.76% | 26.24% | 27.38% | 29.43% |
| Net Margin | 13.89% | 23.09% | 5.81% | 18.74% | 21.75% | 25.34% | 27.83% | 226.73% | 26.75% | 26.46% | 29.21% | 30.96% |
This table shows 12 quarterly periods of Edwards Lifesciences's income statement, from Q2 2026 back to Q3 2023, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow EW's reporting calendar. What is a income statement?